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Abstract: In this paper, we report the study of the loading and the release of curcuminoids by
bioactive glasses (BG) and mesoporous bioactive glasses (MBG). Through a detailed spectroscopic
study, it was possible to determine the amount and the type of molecules released in water and in
simulated body fluid (SBF). In particular, curcumin and K2T21 show a good ability to be released in
di-keto and keto-enolic form, depending from the pH. However, after 24 h, the amount of pristine
curcumin release is very low with a consequent increment of degradation products derived by
curcuminoids. The presence of –OH groups on curcuminoids is a fundamental pre-requisite in order
to obtain a high loading and release in polar solution such as water and SBF. The substrate on which
we loaded the drugs does not seem to affect significantly the loading and the release of the drugs.
The environment, instead, affects the release: for all the drugs, the release in SBF, buffered at pH of
7.4, is slightly worse than the release in water (basic pH values).
Keywords: bioactive glass; curcuminoids; drug release
1. Introduction
Recent developments in bone tissue engineering provided alternative approaches for the repair
of bone defects caused by trauma and infection [1]. Bone repair scaffolds loaded with drugs
(i.e., antibiotics and antitumoral medicaments) and/or growth factors, attract increasing attention since
they can protect against infections but also regulate cell growth and enhance bone regeneration [2–9].
Basically, bone scaffolds should be biocompatible, biodegradable, osteoconductive and, in improved
scaffold designs, they should be able to act as local drug carrier [2,9–14]. Scaffolds are usually made
from tailored combination of inorganic and organic phases, forming composite structures aiming
at replicate the structure and composition of bone tissue [2,3,13,15]. Several bioactive glasses and
bioceramics have been used as the inorganic phase in drug eluting composite scaffolds, including
hydroxyapatite (HA) [6,7,16], calcium phosphate (CaP) [17–19], and Bioglass® [20–23]. Scaffolds
composed of a single inorganic component usually have low drug binding affinity, and thus, they do
not allow a controlled drug release [13]. This is particularly the case for bioactive glass scaffolds derived
from molten glasses [20–23], which present a low specific surface area and do not have a suitable
intrinsic porosity to be used as drug reservoirs [3,10]. Therefore, the sol-gel synthesis methodology
yields high surface area materials. In particular, the sol-gel process coupled with evaporation-induced
self-assembly (EISA) method allows preparing mesoporous bioactive glasses (MBG) (pore diameter:
2–10 nm) [22,24]. In vitro, these materials exhibit the quickest bioactive response among asynthetic
materials. In addition, they display high surface areas and pore volumes, which are suitable features
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in order to host biologically active molecules/drugs [25–27]. In view of these characteristics, MBG
systems can be considered good drug delivery system (DDS). The drug molecules can be hosted within
the mesopores by soaking techniques and then released via a diffusion-based mechanism without
drug-silica interaction [28]. However, the properties of the drugs (dimension and polarity) and the
MBG surfaces (pore dimensions and functional group) could play an important role in the loading and
releasing phases [29].
Between the drugs loaded on bioactive glasses, the antibacterial and anti-inflammatory substances
received much attention. Recently, Malavasi et al., tried to load curcumin on sol-gel (BG) and mesoporous
bioactive glasses (MBG) [30,31] using immersion techniques, obtaining low amount of loaded drug:
0.4% wt of curcumin on powder glass.
Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione], commonly extracted
from the dried rhizomes of Curcuma longa L., presents a wide spectrum of therapeutic properties,
ranging from antioxidant and anti-inflammatory to chemo-preventive and anti-cancer activities [32,33].
Although curcumin has marked biological activity, its relatively poor solubility and stability in
physiological conditions are well documented and represent its main drawbacks [33]. In order to
increase the stability of curcumin, several curcumin-derivate were synthesized [34]. Curcumin and its
analogues undergo keto-enol tautomerism. Concerning the antioxidant activity, the diketo form plays
a key role in the regulation of redox homeostasis induced by curcumin [35], while the keto-enolic form
shows a strong iron chelating ability [36]. Among Curcumin analogues, some β-diketo derivatives
showed improved stability in physiological conditions, and increased antiproliferative activity against
colon cancer cells HCT116 in vitro [33].
In the present contest, we report the study of the loading and release from bioactive glasses and
mesoporous DDS of curcumin and two synthetic derivatives (Figure 1). The aim of the present study
is to optimize the loading conditions in order to increase the amount of curcuminoid in the DDS, and
investigate the released in physiological conditions.
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Figure 1. Structures of the investigated drugs loaded in the bioactive glasses: (a) curcumin; (b) K2T21;
and (c) K2T23.
2. Materials and Methods
2.1. Synthesis of Bioactive Glasses and Curcumininoids
We synthesize a bioactive glass of composition 80SiO2¨15CaO¨5P2O5 (% ol) via sol-gel [37] and
evaporati n induced self-assembly (EISA) [38] methods. We obtained two samples with the same
composition but different porosity: the sol-gel glass (hereafter as BG) was microporous, while the EISA
glass (MBG) was mesoporous [30]. In both cases, we used tetra-ethyl-ortho-silicate (TEOS), calcium
nitrate tetrahydrate and triethyl phosphate (TEP) as precursors for SiO2, CaO and P2O5 respectively.
We used ethanol as solvent, HCl as catalyst and Pluronic P123 (Figure 2) as the self-assembling polymer
in the EISA process. We ground the obtained glasses to a diameter <50 µm.
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The in vitro bioactivity of BG and MBG was confirmed in previous papers [39,40]. In the present
work, we want to evaluate the drug release both in pure distilled water and physiological environment,
thus, we prepared a simulated body fluid (SBF) buffered at pH of 7.4, accordingly to Kokubo [41].
Table 1 shows the comparison between plasma and SBF ions concentrations (expressed as mM).
Table 1. Comparison between the composition (mM) of human plasma and simulate body fluid (SBF).
Na+ K+ Ca2+ Mg2+ Cl´ HPO42´ HCO3´ SO42´
Plasma 142.0 5.0 2.5 1.5 103.0 1.0 27.0 0.5
SBF 142.0 5.7 2.5 1.5 147.8 1.0 4.2 0.5
Curcumin, (3Z-5E)-tert-Butyl-4-hydroxy-6-(3-methoxy-4-hydroxyphenyl)-acrolyl)hexa3,5-dienoate
(K2T21) and (3Z-5E)-tert-Butyl-4-hydroxy-6-(3-methoxyphenyl)-acrolyl)hexa3,5-dienoate (K2T23)
(Figure 1a–c, respectively) were synthesized as previously reported [34].
2.2. Loading of Bioactive Glasses
We performed the loadings through a procedure called “evaporation”, and compared the new
results on the loading with those obtained through immersion technique as reported in a previous
paper [30]. The “evaporation method” can be summarized as follow: 100 mg of glass powder (diameter
< 50 µm) were soaked in 5 mL of the curcuminoid ethanolic solution (1 mg/mL). After 30 min of
stirring at room temperature (rt), we evaporated the solvent under vacuum to dry the glasses, then we
put the glasses in the heater at 70 ˝C for 24 h. After drug loading, the samples were orange-yellow in
color. The samples were characterized by elemental analysis, specific surface area (SSA) and porosity.
The amount of curcuminoids were calculated with respect to blank samples, obtained by soaking the
glass powder in ethanol, dryness under vacuum and treatment at 70 ˝C for 24 h.
2.3. Study of the Drug Release from Bioactive Glasses
We carried on static and dynamic release tests on the loaded samples. Briefly, static tests were
performed as follows: loaded glass powder (50 mg) was suspended in distilled water (50 mL,
glass/solvent ratio 1 mg/mL) in a PE bottle. The suspension was shaken in an orbital shaker (100 rpm)
at 37 ˝C. At time intervals (51, 151, 301, 1 h, 2 h, 3 h, 4 h and 24 h) the suspension was microfiltered
(ø 0.45 µm) on cellulose filter paper, and the obtained solutions were analyzed by UV-Vis spectroscopy.
For the dynamic release tests, 250 mg of loaded glass were dissolved in the solvent medium
(50 mL of pure distilled water or SBF, glass/solution ratio 5 mg/mL) in a PE bottle. The suspension
was shaken in an orbital shaker (100 rpm) at 37 ˝C. At different times (1, 2, 3, 4, 6, 8, 10, 12, 16, 20 and
24 h), the solution was removed to be analyzed, then 50 mL of fresh solvent (pure distilled water or
SBF) were added to re-fill the bottle. The extracted solution was micro-filtered (ø 0.45 µm cellulose
filter paper) and analyzed by UV-Vis spectroscopy.
The concentration of curcuminoids in the solutions was calculated based on calibration curves
(concentration range 0.5–100 µM) by spectrophotometric analysis.
2.4. Instrumental Analysis
Elemental analysis data were collected by a PerkinElmer 2400 CHNS analyzer, the results are
expressed as % (w/w) of the drug with respect to the bioactive glass.
Specific surface area (SSA) and porosity were evaluated for MBG glass before and after soaking in
ethanol solution and evaporation under vacuum. Measurements were performed by N2 adsorption at
´196 ˝C using a Micromeritics ASAP 2020 porosimeter. For SSA determination, data were processed
by employing the BET model. The BJH model was used to analyze mesopores size distribution, and
the “t-plot” (statistical thickness method) was adopted to evaluate the presence of micropores [42,43].
For a review of the applied methods, see Gregg and Sing [44]. Before N2 adsorption measurements, all
samples were outgassed at rt for 24 h (residual pressure: ~10´3 Torr).
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The UV-Vis spectra of the solutions were collected using a Cary 100 UV-visible spectrophotometer
in the 200–600 nm range.
3. Results
3.1. Characterization of the DDSs
Table 2 reports the percentages (w/w) of the drug loaded on the DDS (BG and MBG) using the
“evaporation method”, data were calculated from the results of the CHNS analysis.
Table 2. Percentage (w/w) of the loaded drug on the glass delivery system via evaporation method
(SD = standard deviation obtained by three different replicate determinations).
Glass Drug %drug (w/w) ˘ SD
BG
Curcumin 3.1 ˘ 0.1
K2T21 3.3 ˘ 0.1
K2T23 2.3 ˘ 0.2
MBG
Curcumin 3.9 ˘ 0.2
K2T21 3.1 ˘ 0.1
K2T23 2.4 ˘ 0.1
According to the applied experimental procedure, the maximum percentage of the loaded drug
is 5% (w/w) (5 mg(drug)/100 mg(glass)). The data in Table 2 are below 5% for all curcuminoids and
DDSs, hence the evaporation method allowed to load only 50% of the overall drug. If compared to the
previous results [30], the amount of loaded drugs with the “evaporation methods” is ten times higher
(0.3%/0.4% vs. 2%/4% w/w). With this method, part of the drug molecules ties to the glass pores
through hydrogen bonds, while a portion remains in solution and precipitates on the surface during
solvent evaporation. It is interesting to note that the MBG system is able to load a higher amount
with respect to BG glass only in the case of curcumin, which is the smallest molecule. In addition,
the amounts of curcumin and K2T21 loaded are higher with respect to K2T23 probably due to the
presence of OH groups in the cited molecules, which are able to interact positively with the silanol
(Si-OH) groups on the glass surface.
BET analysis (Table 3) confirms the reduced ability of MBG glass to host drug molecules in
the pores.
Table 3. N2 adsorption analysis performed on MBG sample before and after the soaking in ethanol.
SSA (m2/g) BJH Mesopore Area (m2/g) BJH Average Pore Width (Å)
BG before 120 10 –
BG after 93 3 –
MBG before 472 224 30
MBG after 359 162 30
The solvent clearly decrease the area of mesopores, where it should be possible to host the
curcuminoid molecules.
3.2. Static Release Study
It is well known that curcuminoids, once in water, undergo keto-enol tautomerism, and the two
tautomers have typical absorption maxima at different λmax: 300–380 nm for the diketo form (DK) and
400–470 nm for the keto-enol form (KE). In addition, the curcuminoids in solution originate products
of degradation that absorb mainly in the range of the DK form and below (<300 nm) [45]. Preliminary
analysis of the aqueous drug solutions were performed to select the absorption band to investigate.
The analyses showed that in water:
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(i) the DK form is the most stable one for all the investigated curcuminoids (~300–350 nm); and
(ii) degradation products show strong absorptions below 300 nm and in the range 300–350 nm.
In view of these remarks, we decided to survey and quantify the absorption of the band
attributable to the KE form. Figure 3 shows the results of the static release tests in water. We observed
that both curcumin and K2T21 behaved in a similar way: they were released by the glass in the KE
form and as degradation byproducts. After 15/30 min, they started to convert into diketo form (DK)
and degradation products; the latter are the principal components in solution after 24 h. The structure
of the K2T23 is different from the two previous drugs because of the lack of hydroxyl groups, and thus,
its behavior has been quite different with respect to the other release tests. This molecule is the less
soluble and a very small fraction was released in pure distilled water, undergoing fast degradation.
Indeed, solution obtained from the release tests of both curcumin and K2T21 showed an absorption
band with a maximum at 424 and 422 nm, respectively, the range of the keto-enol (KE) form, while the
solution obtained from the release of K2T23 absorbed only below 300 nm, in the range of the DK form
and degradation products.
In this condition, the maximum release was reached after 30 min with a concentration of 7 and
43 µM for curcumin and K2T21, respectively. On the contrary, as previously reported, the concentration
in water for K2T23 was negligible.
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3.3. Dynamic Release Study
Since bo the BG and the MBG glasses, wh n soaked in pu e water with a ratio of 1 mg/mL
released the drugs only fo the first two hour , we decided to perform the dynamic ts soaking at
5 mg/mL glass/solution ratio. We soaked the same quantity f loaded glasses also for the tests in
SBF. This solid/solution ratio was chosen because it is the same ratio used in bioactivity tests [46].
We performed the release tests over 24 h because after this time the releases were negligible for all the
three drugs.
In Figure 4 we reported the UV-Vis spectra of the experiments of dynamic release performed in
pure water and the cumulative releases of the no degraded drugs, expressed in percentage. Curcumin
(Figure 4a,c) and K2T21 (Figure 4e,g) behaved differently: curcumin was released as a mix of KE form
and degradation produc . K2T21, instead, was released as both KE nd DK forms and degradation
products. Thus, it is confirmed that the resenc of the substitue t in α position between the rbonyl
and enol carbons shifts the equilibrium in favor of the DK form, increasing the stability in aqueous
medium [34]. For K2T21, the tests performed over the BG and MBG did not show significant differences.
Curcumin, instead, showed a lower and more controlled release from the MBG with respect to the BG.
From the release curves, it is possible to notice that K2T21 was released in a higher quantity compared
to curcumin, and this is strongly related to its higher stability in solution [34]. K2T23 (Figure 4i,k)
always behaved in the same way, regardless of the glass or the concentration used. We detected only
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a very low signal of its KE form, while the most intense signals, below 350 nm, were the ones of its
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The UV-Vis spectra of the dynamic release tests performed in SBF are reported in Figure 5
(curcumin and K2T21) and Figure 6 (K2T23), together with the cumulative release expressed in
percentage. K2T23 performed the same as in pure water; that is, all its spectra showed bands in
the range of the degradation products. In SBF, the quantitation of K2T23 was prevented because
this compound is completely released as byproducts. Regarding curcumin and K2T21, we could not
compare how the two drugs behaved in SBF, as we did in pure water, but we noticed that in this
environment, the substrate morphology (MBG vs. BG) did not really affect the releases. Spectra of
curcumin releases showed three bands: the KE with maximum at 424 nm, the DK at 357 nm and one
below 300 nm due to the degradation products (mainly vanillin [31]). All of the signals were quite
intense at the beginning, then after 6–8 h of soaking the KE and the DK signals became much less
intense than the band of the degradation products. The spectra of the solutions released from K2T21
showed a weak shoulder at 450 nm, attributable to the absorption of the KE form, and two intense
bands at 357 nm (DK form) and below 300 nm (degradation products).
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We tried to linearize the releases of the drugs through the Higuchi equation, as we already did
in [30]. The linearizations were not possible, thus the mechanism of release is not attributable only to
the diffusion.
5. Conclusions
It is possible to conclude that BG and MBG systems could be employed to deliver drugs that are
highly instable in aqueous environments. The data collected to date are promising and encourage us
to continue the study on the possibility to obtain drug delivery systems by coupling curcuminoids and
bioactive glasses.
The ability of mesoporous-sol-gel (MBG) and sol-gel bioactive glasses (BG) to act as DDS was
confirmed. In particular, Curcumin and K2T21 were released continually over 24 h in KE and DK
form. However, with the increment of the time the amount of degraded drugs released were increased.
The amount of loaded drugs depends on the dimension and the polarity (presence of –OH groups) of
curcumin-derivates, while the release depends on the two previous factors and on the type of solution
where the DDS was soaked.
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